CytoAgents is a life sciences startup focused on the development of its signature drug candidate, GP1681, which treats conditions, diseases and disorders associated with Cytokine Release Syndrome. The company raised a $6 million seed round in August 2021, and has successfully completed Phase I clinical trials so far.